Heidelberg Pharma AG
HPHA
Rank in Stocks
#19083
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.46
Last synced: 2026-11-09
Market Cap
$114.99M
Change (1 day)
3.02%
Change (1 year)
-32.01%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heidelberg Pharma AG (HPHA)
Category
Healthcare
EPS for Heidelberg Pharma AG (HPHA)
EPS as of August 2026 TTM: $-0.71
According to Heidelberg Pharma AG's latest financial reports, its current EPS (TTM) is $-0.71. At the end of 2025 the company had an EPS of $-1.06, a decrease compared to its 2024 EPS of $-0.44.
EPS history for Heidelberg Pharma AG from 2006 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.71 | -32.67% |
| 2025 | $-1.06 | 137.54% |
| 2024 | $-0.44 | -7.28% |
| 2023 | $-0.48 | -13.27% |
| 2022 | $-0.55 | -40.54% |
| 2021 | $-0.93 | 27.60% |
| 2020 | $-0.73 | 83.56% |
| 2019 | $-0.40 | -14.50% |
| 2018 | $-0.46 | -48.70% |
| 2017 | $-0.90 | 287.99% |
| 2016 | $-0.23 | -70.59% |
| 2015 | $-0.79 | -3.53% |
| 2014 | $-0.82 | -0.88% |
| 2013 | $-0.83 | -53.46% |
| 2012 | $-1.78 | 170.47% |
| 2011 | $-0.66 | -90.13% |
| 2010 | $-6.67 | 25.27% |
| 2009 | $-5.33 | -34.14% |
| 2008 | $-8.09 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,294.20% |
US
|
|
| $-7.07 | 890.61% |
US
|
|
| $-5.29 | 641.21% |
AU
|
|
| $12.88 | -1,904.69% |
BE
|
|
| $21.56 | -3,120.88% |
NL
|
Questions about Heidelberg Pharma AG's earnings per share (EPS)
What is Heidelberg Pharma AG's earnings per share (EPS)?
Heidelberg Pharma AG's earnings per share (EPS) over the last twelve months is $-0.71, as of Aug 2026.
What was Heidelberg Pharma AG's earnings per share (EPS) in 2025?
In 2025, Heidelberg Pharma AG's earnings per share (EPS) was $-1.06, compared with $-0.44 in 2024.
How has Heidelberg Pharma AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Heidelberg Pharma AG's earnings per share (EPS) was highest in 2024 ($-0.44) and lowest in 2025 ($-1.06).
How does Heidelberg Pharma AG's earnings per share (EPS) compare with similar companies?
Heidelberg Pharma AG's earnings per share (EPS) ($-0.71) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.